<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE ichicsr>
<ichicsr lang="en">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>c9e828f9-9ffe-11ee-b786-28dfeb6bed73-BIO</messagenumb>
<messagesenderidentifier>simplesafety</messagesenderidentifier>
<messagereceiveridentifier>ss</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20230627181515</messagedate>
</ichicsrmessageheader>
<safetyreport>
<safetyreportversion>0</safetyreportversion>



<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>20230627</transmissiondate>
<reporttype>1</reporttype>
<serious>2</serious>










<authoritynumb>3401005100615202300019</authoritynumb>




<sender>

<senderorganization>simplesafety</senderorganization>
</sender>
<receiver>

<receiverorganization>ss</receiverorganization>
</receiver>
<patient>
<patientinitial>unknown</patientinitial>




<patientbirthdateformat>102</patientbirthdateformat>
<patientbirthdate>19830613</patientbirthdate>
<patientonsetage>40</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>


<patientagegroup>5</patientagegroup>
<patientweight>75.0</patientweight>

<patientsex>2</patientsex>




<patientdeath>
<patientdeathdateformat>102</patientdeathdateformat>


</patientdeath><patientdeathcause>

<patientdeathreport>0</patientdeathreport>
</patientdeathcause><medicalhistoryepisode>

<patientepisodename>10043887</patientepisodename>






</medicalhistoryepisode><reaction>
<primarysourcereaction>Abnormal eye sensation</primarysourcereaction>





<reactionstartdateformat>102</reactionstartdateformat>
<reactionstartdate>20230613</reactionstartdate>






<reactionoutcome>2</reactionoutcome>
</reaction><drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>Naphazoline Hydrochloride and Chlorphenamine Maleate and Vitamin B12 Eye Drops</medicinalproduct>






<drugstructuredosageunit>031</drugstructuredosageunit>






<drugdosageform>Eye Drops Solution</drugdosageform>
<drugadministrationroute>047</drugadministrationroute>

<drugindication>10043888</drugindication>
<drugstartdateformat>102</drugstartdateformat>
<drugstartdate>20230612</drugstartdate>
<drugenddateformat>102</drugenddateformat>
<drugenddate>20230614</drugenddate>


<actiondrug>0</actiondrug>


<activesubstance>
<activesubstancename>Naphazoline Hydrochloride and Chlorphenamine Maleate and Vitamin B12 Eye Drops</activesubstancename>
</activesubstance>
<drugreactionrelatedness>


<drugassessmentsource>Reporter</drugassessmentsource>
<drugassessmentmethod>Global Introspection</drugassessmentmethod>
<drugresult>possibly</drugresult>
</drugreactionrelatedness><drugreactionrelatedness>


<drugassessmentsource>Company</drugassessmentsource>
<drugassessmentmethod>Global Introspection</drugassessmentmethod>
<drugresult>possibly</drugresult>
</drugreactionrelatedness></drug><summary>
<narrativeincludeclinical>On June 12, 2023, the consumer, Li Fen, female, 40 years old, came to our pharmacy to purchase Naphazoline Hydrochloride and Chlorphenamine Maleate and Vitamin B12 Eye Drops due to tired eyes. The pharmacist informed the route and dosage, one drop three times a day, for external application (dropping eyes), and instructed her precautions for use. Two days later, the consumer came to consult and said that she had eye discomfort during the medication period and suspected that it was related to Naphazoline Hydrochloride and Chlorphenamine Maleate and Vitamin B12 Eye Drops. The pharmacist suggested to stop the medication immediately for observation and to seek medical attention if necessary. The next day, the consumer was followed up by phone and told that the symptoms had improved.</narrativeincludeclinical>
</summary></patient></safetyreport>
</ichicsr>